A Comparison of Vagal Nerve Stimulation and Responsive Neurostimulation for the Treatment of Medically Refractory Complex Partial Epilepsy
A Comparison of Vagal Nerve Stimulation and Responsive Neurostimulation for the Treatment of Medically Refractory Complex Partial Epilepsy
复制标题
DOI：
10.1159/000492232
复制
发表时间：
2018-01-01
影响因子：
1.7
通讯作者：
Patra, Sanjay E.
中科院分区：
文献类型：
--
作者：
Ellens, Nathaniel R.;Elisevich, Kost;Patra, Sanjay E.
背景资料：迷走神经刺激（VNS）和反应性神经刺激（RNS）等神经调节应用是治疗继发于复杂部分性癫痫发作的难治性癫痫的安全有效的策略，但研究人员尚未比较其疗效。目的：本研究的目的是比较VNS和RNS在降低继发于复杂部分性癫痫发作的难治性癫痫受试者的癫痫发作频率和并发症发生率方面的疗效。研究方法：这是对30例难治性复杂部分性癫痫患者的回顾性病历审查，这些患者于2012年6月至2016年1月期间在一家机构接受了VNS或RNS置入术。平均随访19个月。发现癫痫发作频率降低和并发症。结果：迷走神经刺激（66%）和迷走神经刺激（58%）的中位发作频率降低相似。VNS（15%）和RNS（18%）之间无严重发病率或死亡率，轻微并发症的发生率相似。结论：我们发现VNS和RNS降低中位癫痫发作频率相似，但发病率和死亡率无差异。随着VNS和RNS治疗的改善，需要进一步的前瞻性研究。(C)2018 S. Karger AG，巴塞尔
Background: Neuromodulatory applications such as vagus nerve stimulation (VNS) and responsive neurostimulation (RNS) are safe and effective strategies for medically intractable epilepsy secondary to complex partial seizures, but researchers have yet to compare their efficacies. Objective: The goal of this study is to compare VNS and RNS efficacy at reducing seizure frequency and complication rates in subjects with medically intractable epilepsy secondary to complex partial seizures. Methods: This is a retrospective chart review of 30 patients with medically intractable complex partial epilepsy, who underwent either VNS or RNS placement at a single institution between June 2012 and January 2016. There was a mean follow-up of 19 months. Seizure frequency reduction and complications were identified. Results: The median seizure frequency reduction was similar for VNS (66%) and RNS (58%). There was no major morbidity or mortality, and the frequency of minor complications was similar between VNS (15%) and RNS (18%). Conclusion: We found that VNS and RNS reduced the median seizure frequency similarly with no difference in morbidity or mortality. Further prospective studies are warranted as VNS and RNS therapy improves over time. (C) 2018 S. Karger AG, Basel